Certara, the global leader in model-informed drug development and regulatory science, today announced the launch of its Quantitative Systems Pharmacology (QSP) Immuno-oncology Simulator Consortium.
The QSP consortium aims to combine computational modelling and experimental methods to examine the mechanistic relationships between a drug, the biological system, and the disease process.
QSP will accomplish this by integrating quantitative drug data with knowledge of the drug’s mechanism of action. If successful, this process could facilitate the evaluation of complex, heterogeneous diseases such as cancer, immunological, metabolic and central nervous system diseases that require multiple therapies.
‘We believe that the key to developing novel, new immuno-oncology therapies will be selecting optimal combination therapies, dose regimens and biomarkers, tailored to specific cancers and patient populations. But there are so many possible therapy combinations, and the biological and pathological processes involved are so complex, that quantitative, mechanistic models of the interactions between the tumour, immune system and therapies have to be created first to guide development decisions. That is where the QSP Immuno-oncology Simulator will come in,’ said Certara’s Simcyp president and managing director Dr Steve Toon.
Modelled after Certara’s Simcyp Consortium, QSP brings together leading biopharmaceutical companies in a pre-competitive environment to develop cooperatively a QSP Immuno-oncology Simulator that can model clinical populations of cancer patients.
The Consortium plans to capture the pertinent biology, pharmacology, and variation between individuals in sufficient detail so that the Simulator can guide and improve clinical development of immuno-oncology therapies.Immuno-oncology therapies work by mobilising a patient’s own immune system to fight their cancer.
Recent successes with immune checkpoint inhibitors, such as PD1 and PD1L, have made immuno-oncology one of the most competitive and fastest-growing areas of pharmaceutical R&D. The global market for immuno-oncology therapies is expected to exceed $45 billion by 2025.1 But it is also a very complex, challenging field as illustrated by the clinical trial failures.
‘The QSP Immuno-oncology Simulator will allow researchers to explore different therapeutic combinations, even drugs using different modalities, within a virtual population. It will enable sponsors to answer a lot of ‘what-if’ questions, providing input and guidance for clinical development,’ said Professor Piet van der Graaf, PharmD, PhD, Certara Vice President, QSP.
‘We anticipate that QSP modelling will follow a similar adoption curve to physiologically-based pharmacokinetic (PBPK) modelling, which is now standard practice within the drug development process and an expected component of regulatory submissions,’ added Professor van der Graaf. ‘In fact, QSP has been identified as a promising technology and incorporated into the US Food and Drug Administration (FDA) model-informed drug development roadmap.’
- Cavnar S, Valencia P, Brock J, Wallenstein J, Panier V. The immuno-oncology race: myths and emerging realities. Nat Rev Drug Discov. 2017;16(2):83-4.